Download full report with analyst certification and important disclosures
Feb 16 2021, 08:10 GMT
DSM-Firmenich
Robust FY 2021 guidance provided
- Sectors : Foods
- Companies : DSM-Firmenich
DAVY VIEW
DSM’s Q4 result showcases strong momentum across both its Animal and Human Nutrition platforms, bolstered by strong demand for immunity-related products. The EBITDA contribution from Glycom in Q4 was notable. The Materials division saw a strong recovery through Q4. Nutrition guidance infers strong confidence on delivery for the year ahead. We continue to recommend the shares.
